Thrombosis and hemorrhage experienced by hospitalized children with SARS-CoV-2 infection or MIS-C: Results of the PICNIC registry

Sarah Tehseen1 | Suzan Williams2 | Joan Robinson3 | Shaun K. Morris4 | Ari Bitnun4 | Peter Gill4 | Tala El Tai4 | Ann Yeh4 | Carmen Yea4 | Rolando Ulloa-Gutierrez5 | Helena Brenes-Chacon5 | Adriana Yock-Corrales5 | Gabriela Ivankovich-Escoto5 | Alejandra Soriano-Fallas5 | Jesse Papenburg6 | Marie-Astrid Lefebvre6 | Rosie Scuccimarr6 | Alireza Nategian7 | Behzad Haghighi Ask7 | Rachel Dwilow8 | Jared Bullard8 | Suzette Cooke9 | Lea Restivo9 | Alison Lopez10 | Manish Sadarangani10,11 | Ashley Roberts10 | Michelle Forbes12 | Nicole Le Saux13 | Jennifer Bowes13 | Rupeena Purewal14 | Janell Lautermilch14 | Ann Bayliss15 | Jacqueline K. Wong16 | Kirk Leifso17 | Cheryl Foo18 | Luc Panetta19 | Fatima Kakkar19 | Dominique Piche20 | Isabelle Viel-Theriault21 | Joanna Merckx22 | Lani Lieberman on behalf of the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC)23

1 Department of Laboratory medicine and Pediatrics, University of Saskatchewan, SHA, Saskatoon, Saskatchewan, Canada
2 Division of Hematology Oncology, Hospital for Sick Children, Toronto, Ontario, Canada
3 Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
4 Department of Pediatrics, Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada
5 Department of Pediatrics, Hospital Nacional de Niños “Dr. Carlos Sáenz Herrera,” Caja Costarricense de Seguro Social (CCSS), San José, Costa Rica
6 Department of Pediatrics, McGill University, Montreal, Quebec, Canada
7 Department of Pediatrics, Iran University of Medical Sciences, Tehran, Iran
8 Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada
9 Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
10 Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
11 Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
12 Department of Pediatrics, Western University, London, Ontario, Canada
13 Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
14 Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
15 Department of Pediatrics, Trillium Health Partners, Mississauga, Ontario, Canada
16 Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
17 Department of Pediatrics, Queen’s University, Kingston, Ontario, Canada
18 Department of Pediatrics, Memorial University, St John’s, Newfoundland and Labrador, Canada
19 Department of Pediatrics, Université du Montréal, Montreal, Quebec, Canada
20 Department of Pediatrics, Université du Montréal, Montreal, Quebec, Canada

Abbreviations: BMI, body mass index; CHD, congenital heart disease; CVC, central venous catheters; ICU, intensive care unit; INR, international normalized ratio; ISTH, International Society of Thrombosis and Hemostasis; MIS-C, multisystem inflammatory syndrome in children; PTT, partial thromboplastin time; SIC, sepsis-induced coagulopathy; VTE, venous thromboembolism; WHO, World Health Organization.
Abstract

Introduction: Coagulopathy and thrombosis associated with SARS-CoV-2 infection are well defined in hospitalized adults and leads to adverse outcomes. Pediatric studies are limited.

Methods: An international multicentered (n = 15) retrospective registry collected information on the clinical manifestations of SARS-CoV-2 and multisystem inflammatory syndrome (MIS-C) in hospitalized children from February 1, 2020 through May 31, 2021. This sub-study focused on coagulopathy. Study variables included patient demographics, comorbidities, clinical presentation, hospital course, laboratory parameters, management, and outcomes.

Results: Nine hundred eighty-five children were enrolled, of which 915 (93%) had clinical information available; 385 (42%) had symptomatic SARS-CoV-2 infection, 288 had MIS-C (31.4%), and 242 (26.4%) had SARS-CoV-2 identified incidentally. Ten children (1%) experienced thrombosis, 16 (1.7%) experienced hemorrhage, and two (0.2%) experienced both thrombosis and hemorrhage. Significantly prevalent prothrombotic comorbidities included congenital heart disease (p-value .007), respiratory support (p-value .006), central venous catheter (CVC) (p = .04) in children with primary SARS-CoV-2 and in those with MIS-C included respiratory support (p-value .03), obesity (p-value .002), and cytokine storm (p = .012). Comorbidities prevalent in children with hemorrhage included age > 10 years (p = .04), CVC (p = .03) in children with primary SARS-CoV-2 infection and in those with MIS-C encompassed thrombocytopenia (p = .001) and cytokine storm (p = .02). Eleven patients died (1.2%), with no deaths attributed to thrombosis or hemorrhage.

Conclusion: Thrombosis and hemorrhage are uncommon events in children with SARS-CoV-2; largely experienced by those with pre-existing comorbidities. Understanding the complete spectrum of coagulopathy in children with SARS-CoV-2 infection requires ongoing research.

KEYWORDS
COVID-19, hemorrhage, MIS-C, pediatric, SARS-CoV-2, thrombosis, c

1 | INTRODUCTION

In hospitalized adults, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been associated with coagulopathy, significantly elevated D-dimers, and venous thromboembolism (VTE). These complications lead to adverse outcomes in hospitalized adults, including increased mortality.1-5 The etiology of the coagulopathy has been hypothesized to be related to a homeostatic imbalance associated with infections, similar to sepsis-induced coagulopathy (SIC). However, when compared to SIC, coagulopathy associated with SARS-CoV-2 is characterized by no or mild thrombocytopenia, higher rates of thrombosis, and a greater increase in D-dimer levels with infrequent hemorrhagic events.6-8

Children infected with SARS-CoV-2 are commonly asymptomatic or present with mild gastrointestinal (GI) or respiratory symptoms with a less than 1% mortality rate.9-12 Children with underlying medical conditions such as chronic lung disease, congenital heart disease (CHD), obesity, and age <1 year are at an increased risk of severe illness...
with multiorgan dysfunction. Reports of hematologic complications of SARS-CoV-2 infection or multisystem inflammatory syndrome (MIS-C) in children are limited with recent observational studies reporting an increased risk of thrombosis in children over 12 years of age with MIS-C. However, the current understanding of the clinical presentation of coagulopathy, optimal management, complications, and impact on disease prognosis is limited.

Given the impact of SARS-CoV-2 on hemostasis and its association with mortality in adults, understanding the spectrum of coagulopathy and its association with outcome in children is critical. The objectives of this study were to (a) determine the prevalence of hemorrhage and/or thrombosis; (b) describe the characteristics of hemorrhage and thrombosis with management; and (c) assess the relationship between thrombotic and bleeding complications and underlying comorbidities in hospitalized children with SARS-CoV-2 and MIS-C.

2 METHODS

A multisite international registry was created by the PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) investigators, with the aim to collect data regarding clinical presentation, treatment, and outcome of hospitalized children up to 18 years of age with SARS-CoV-2 infection or MIS-C diagnosis. Fifteen hospitals participated in the study across three countries (Canada, Costa Rica, and Iran). Children who were hospitalized between February 1, 2020 and May 31, 2021, and diagnosed with SARS-CoV-2 or MIS-C were eligible for inclusion. This retrospective cohort sub-study presents data on coagulopathy, hemorrhage, and thrombosis among hospitalized children with SARS-CoV-2 or MIS-C.

Cases were identified by screening admission lists for children with positive testing for SARS-CoV-2 or MIS-C. Children were classified with primary SARS-CoV-2 if the infection led to hospital admission or prolonged the hospital stay for an existing admission. A child was classified with incidental SARS-CoV-2 infection if the infection caused mild or no symptoms, was not the reason for hospital admission, and did not extend the duration of the hospital stay. Children were classified with MIS-C based on the World Health Organization (WHO) criteria (Figure 1)

Data collected included patient demographics, underlying risk factors for both pro-hemorrhagic and/or prothrombotic conditions, clinical presentation, including new hemorrhagic or thrombotic events during hospitalization, disease course, and severity as determined by admission to the intensive care unit (ICU), use of cardiopulmonary supports, treatments, and complications. Presence of hemorrhage was based on documentation from the clinical chart and classified according to the WHO-modified bleeding scale (Table S3). Thrombotic events were identified based on any evidence of vessel occlusion on radiographic imaging with or without clinical features. Cytokine storm was defined based on the classification criteria from the Pediatric Rheumatologic Collaborative (Table S4). Prothrombotic risk factors were defined based on the ISTH (International Society of Thrombosis and Hemostasis) criteria and included age >10 years, previous thrombosis, presence of a central venous catheter (CVC), active cancer, obesity, inherited thrombophilia, congenital/acquired heart disease, autoimmune disorders, hemoglobinopathy, systemic infection, use of respiratory support, or ICU admission. Hemorrhagic risk factors were defined based on review of pediatric and adult literature and included age >10 years, male gender, CVC, thrombocytopenia, CHD, use of anticoagulation/antiplatelet therapy, congenital bleeding disorder, renal failure, systemic infection, and ICU admission. Systemic infection was defined as laboratory detection of any virus, bacteria, or fungi concurrent with SARS-CoV-2 infection and treated with antimicrobials. Obesity was defined as documentation of obesity in the medical record and not based on the body mass index (BMI) criteria. Respiratory support was defined as the use of high-flow nasal cannula, noninvasive ventilation (BiPAP/CPAP), mechanical ventilation, or extracorporeal membrane support (ECMO) during hospital admission. Laboratory parameters included platelet count, international normalized ratio (INR), partial thromboplastin time (PTT), fibrinogen, serum ferritin levels, C-reactive protein, erythrocyte sedimentation rate (ESR), D-dimer, triglycerides, liver function tests (AST, ALT, bilirubin), brain natriuretic peptide (BNP), troponin, urea, creatinine, and serum sodium. Data on clinical manifestations of bleeding and/or thrombosis, and management of these symptoms (including use of antithrombotic medications as prophylaxis and treatment) was recorded.

Ethics approval was obtained at all sites and the need for consent was waived. The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines were followed to ensure accurate and complete reporting of all observations for this retrospective cohort study. The investigator of PICNIC registry (Joan Robinson) classified patients as MIS-C, primary infection, or incidental SARS-CoV-2, whereas the principal investigator (Sarah Tehseen) performed data review to ensure that all cases classified as having a hemorrhage, thrombosis, or cytokine storm met the study definitions.

Data were collected and managed using REDCap electronic data capture tools. From November 17, 2020 onwards, incidental SARS-CoV-2 cases had only demographic data collected. Therefore, these cases were not included in descriptive or comparative statistics (Figure 1). The “incidental SARS-CoV-2” cases entered before November 2020 had demographic and clinical data entered. Hence, they were included in descriptive statistics but not in the comparative analyses.

Comparative statistics were performed separately for patients with primary SARS-CoV-2 infection and MIS-C. Descriptive statistics were performed for continuous and categorical variables based on distribution of data. Comparisons of continuous variables between patients with hemorrhage and thrombosis and those without hemorrhage or thrombosis were conducted using parametric (independent sample t-tests) and nonparametric (Wilcoxon signed rank) tests depending on the distribution of data (normal distribution vs. non-normal distribution). Categorical variables were compared using chi-square or Fisher’s exact test among patients with hemorrhage or thrombosis compared with those without hemorrhage or thrombosis. A p-value of .05 was considered statistically significant. All data were analyzed using SAS version 9.4.
FIGURE 1  Classification of children enrolled in Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) registry with number of events of hemorrhage and thrombosis
TABLE 1  Demographic features of hospitalized children infected with SARS-CoV-2 or MIS-C (N = 915)

|                                | All patients (N = 915) | Primary SARS-CoV-2 (N = 385) | MIS-C (N = 288) | Incidental SARS-CoV-2 (N = 242) |
|--------------------------------|------------------------|-------------------------------|----------------|-------------------------------|
| Age (years); median (IQR)      | 4.6 (1.1–11)           | 3 (0.8–11)                    | 6.1 (3–10)*    | 4.3 (0.9–12)                 |
| Gender (male), N (%)           | 561 (74%)              | 282 (73%)                     | 162 (57%)      | 43 (17%)                     |
| Total number of episodes of hemorrhage and thrombosis, N (%) |                        |                               |                |                               |
| Thrombosis                     | 10 (1.0%)              | 5 (1.3%)                      | 3 (1%)         | 2 (0.8)                      |
| Hemorrhage                     | 16 (1.7%)              | 11 (2.8%)                     | 4 (1.8%)       | 1 (0.4%)                     |
| Hemorrhage and thrombosis      | 2 (0.2%)               | 0                             | 2 (0.7%)       | 0                            |
| Other clinical outcomes, N (%) |                        |                               |                |                               |
| ICU admission                  | 256 (28%)              | 117 (30%)                     | 116 (40%)      | 23 (9.5%)                    |
| Respiratory support            | 136 (15%)              | 111 (29%)                     | 21 (8.6%)      | 4 (1.6%)                     |
| Death                          | 11 (1.2%)              | 10 (2.5%)                     | 0              | 1 (0.4%)                     |
| Anticoagulation therapy, N (%) |                        |                               |                |                               |
| Antiplatelet therapy           | 162 (18%)              | 18 (4.6%)                     | 114 (39.5)**   | 0                            |
| Anticoagulation                | 139 (15%)              | 58 (15%)                      | 49 (17%)       | 1 (0.4%)                     |
| Anticoagulation and antiplatelet therapy | 30                    | 0                             | 30 (10%)       | 0                            |
| Rationale for use of anticoagulation, N (% of total patients on anticoagulation, N = 139) | |                               |                |                               |
| Treatment of new thrombus      | 9 (6.5%)               |                               |                |                               |
| Thrombosis prophylaxis in MIS-C| 79 (56%)               |                               |                |                               |
| Thrombosis prophylaxis for other indications | 51 (37%)               |                               |                |                               |
| Pharmacologic agents, N (% of total number on anticoagulation in each patient category) |                     |                               |                |                               |
| Unfractionated heparin (UFH)   | N = 139                | N = 58                        | N = 79         |                               |
|                                | 28 (20%)               | 20 (34%)                      | 7 (9%)         | 1                            |
| Low molecular weight heparin (LMWH) | 82 (59%)               | 34 (59%)                      | 47 (59%)       | 1                            |
| Direct oral anticoagulants (DOAC) | 29 (21%)               | 4 (7%)                        | 25 (32%)       | 0                            |

Note: None of the patients were receiving prophylactic or therapeutic anticoagulation prior to the current admission for SARS-CoV-2 infection/MIS-C. Age: age in years upon hospitalization. Abbreviations: ICU, intensive care unit; IQR, interquartile range; MIS-C, multisystem inflammatory syndrome. *Differences were significant at a p-value of < .001. **p-Value of .02. & Prothrombotic risk factors: low cardiac output, coronary aneurysms, and ≥2 prothrombotic factors (such as high D-dimer, CVC, systemic infection, etc.).

3 RESULTS

Nine hundred eighty-five children were included in the registry; complete information available for 915 patients. Three hundred eighty-five (385/915; 42%) children were diagnosed with primary SARS-CoV-2 infection, 288 (288/915; 31%) with MIS-C, and 242 (242/915; 26.4%) with incidental SARS-CoV-2. Seventy patients with incidental SARS-CoV-2 had only demographic data entered (Table 1, Figure 1). The prevalence of thrombosis was 1.3% (5/385) in children with primary SARS-CoV-2 infection, 1.7% (5/288) in patients with MIS-C, and 0.8% (2/242) in children with incidental SARS-CoV-2 infection. The prevalence of hemorrhage was 2.8% (11/385) with primary SARS-CoV-2 infection, 2.1% (6/288) with MIS-C, and 0.4% (1/242) with incidental SARS-CoV-2. One hundred seventy-seven (19%) children were transferred to the ICU, and 11 (1.2%) died during the admission. None of the deaths were related to thrombotic or hemorrhagic events. Reasons for death included respiratory failure secondary to SARS-CoV-2 infection (n = 9/11; 80%), multiorgan failure in the setting of cytokine storm (n = 1/11; 10%), and deaths unrelated to SARS-CoV-2 (n = 1/11; 10%) (sudden infant death syndrome (SIDS). Ten children who died had underlying comorbidities, including chromosomal abnormalities, cancer, chronic kidney, and lung disease.

Twelve patients (12/915; 1.3%) developed new thromboses; five (5/385; 1.3%) with primary SARS-CoV-2 infection, five (5/288; 1.7%) with MIS-C, and two (2/242; 0.8%) with incidental SARS-CoV-2 infection (Table 2). None of the patients who developed thrombosis...
| Age (years) | Sex | Anatomic site | Case definition | Underlying comorbidities | ICU transfer | Treatment | Prophylaxis | SARS-CoV-2 or MIS-C treatment | Additional history |
|------------|-----|---------------|-----------------|--------------------------|-------------|-----------|------------|-----------------------------|------------------|
| 1          | 0.2 | M             | Deep venous     | Primary SARS-CoV-2 infection | Yes         | LMWH     | LMWH       | None                        |                  |
| 2          | 1   | M             | Deep venous -CVC related | Primary SARS-CoV-2 infection | Yes         | LMWH     | LMWH       | None                        |                  |
| 3          | 3   | F             | Deep venous-PICC line related | Primary SARS-CoV-2 infection | No          | None      | None       | None                        |                  |
| 4          | 1   | F             | Femoral artery  | Primary SARS-CoV-2 infection | Yes         | UFH       | None       | Tocilizumab                  | Cytokine storm, patient died |
| 5          | 12  | F             | Large pulmonary embolism | Primary SARS-CoV-2 infection | No          | LMWH     | None       | None                        |                  |
| 6          | 9   | M             | Cardiac         | MIS-C                   | Yes         | LMWH     | LMWH       | IVIG, anakinra               | Cytokine storm   |
| 7          | 5   | M             | Cardiac left ventricular | MIS-C                   | Yes         | LMWH     | None       | IVIG, anakinra aspirin       | Cytokine storm   |
| 8          | 9   | F             | Internal jugular vein, right iliac vein, and segmental pulmonary artery with infarct | MIS-C | No | LMWH | None | IVIG | 30 days post-SARS-CoV-2 infection, Patient was seropositive |
| 9∞         | 10  | M             | Pulmonary micro-embol | MIS-C                   | No          | LMWH     | DOAC       | IVIG, steroids               | Also had GI hemorrhage |
| 10∞        | 6   | M             | Renal artery infarcts | MIS-C                   | Yes         | None      | None       | IVIG, aspirin                | Also had hematuria |
| 11         | 11  | M             | Internal jugular vein | Incidental SARS-CoV-2 infection | No | LMWH | None | None | Mastoiditis |
| 12         | 3   | M             | Superficial venous upper extremity, Small CSVT | Incidental SARS-CoV-2 infection | No | None | None | IVIG | 15 days post-SARS-CoV-2 infection, seropositive |

Note: Age: age in years upon hospital admission.
Abbreviations: CSVT, cerebral venous sinus thrombosis; CVC, central venous catheter; DOAC, direct oral anticoagulants; GI, gastrointestinal; IVIG, intravenous immune globulin; LMWH, low molecular weight heparin; MIS-C, multisystem inflammatory syndrome in children; MOF, multiorgan failure; PICC, peripherally inserted central catheter; UFH, unfractionated heparin.

1 Intraocular communication, patent ductus arteriosus, congestive heart failure, and pulmonary hypertension.
2 Pulmonary Hypertension, Patent ductus arteriosus.
3 New autoimmune conditions that developed after SARS-CoV-2 infection.∞ Patients 9 and 10 also had hemorrhage and hence mentioned in Table 4 as well.
Table 3: The prevalence of prothrombotic comorbidities in children hospitalized with SARS-CoV-2 infection or MIS-C

| Prothrombotic risk factors | No thrombosis (N = 380) | Thrombosis (N = 5) | p-Value |
|---------------------------|--------------------------|-------------------|---------|
| **Children with Primary SARS-CoV-2 Infection (N = 385)** | | | |
| Systemic infection        | 225 (59%)                | 2 (40%)           |         |
| ICU admission             | 114 (30%)                | 3 (60%)           |         |
| Age ≥10 years             | 92 (24%)                 | 1 (28.6%)         | <.00    |
| Respiratory support       | 100 (26%)                | 5 (100%)          |         |
| Obesity                   | 41 (11%)                 | 1 (20%)           |         |
| Cancer                    | 35 (9%)                  | 0                 |         |
| Presence of CVC           | 27 (7%)                  | 2 (40%)           | .04     |
| Cytokine storm            | 5 (1.3%)                 | 1 (20%)           |         |
| Congenital heart disease  | 9 (2.4%)                 | 2 (40%)           | .007    |
| Hemoglobinopathy          | 9 (2.4%)                 | 0                 |         |
| Inherited thrombophilia   | 0                        | 0                 |         |
| Previous history of thrombosis | 4 (1%)                 | 0                 |         |

| **Children with MIS-C (N = 288)** | No thrombosis (N = 283) | Thrombosis (N = 5) | p-Value |
|-----------------------------------|--------------------------|-------------------|---------|
| ICU admission                      | 114 (40%)                | 2 (40%)           |         |
| Age ≥10 years                      | 65 (23%)                 | 1 (20%)           | .03     |
| Respiratory support                | 19 (7%)                  | 2 (40%)           |         |
| Systemic infection                 | 56 (20%)                 | 1 (20%)           |         |
| Presence of CVC                    | 14 (5%)                  | 1 (20%)           |         |
| Obesity                            | 6 (2%)                   | 3 (60%)           | .002    |
| Cancer                             | 3 (1%)                   | 0                 |         |
| Cytokine storm                     | 9 (3%)                   | 2 (40%)           | .012    |
| Congenital heart disease           | 0                        | 0                 |         |
| Inherited thrombophilia            | 0                        | 1 (20%)           |         |
| Previous history of thrombosis     | 1 (0.3%)                 | 0                 |         |

Note: Respiratory support: use of high-flow nasal cannula, noninvasive ventilation (CPAP, BiPAP), mechanical ventilation, or ECMO. Abbreviations: age, age ≥10 years upon admission to hospital; CVC, central venous catheter; ECMO, extracorporeal membrane support; ICU, intensive care unit; MIS-C, multisystem inflammatory syndrome in children.

During hospitalization, a previous history of thrombosis occurred in two of the 12 patients with thrombosis developed autoimmune conditions (Guillain–Barre and antiphospholipid antibody syndrome) following infection with SARS-CoV-2 and three of 12 developed cytokine storm. Two patients with MIS-C and thrombosis (2/5; 40%) had hemorrhage as well. Most patients with thrombosis (9/12; 75%) received standard pediatric anticoagulation management (low molecular weight or unfractionated heparin). Data on the dose, time, duration, and monitoring of anticoagulation were not available. The thrombotic events in those patients who did not receive anticoagulation included (a) a small CSVT (cerebral venous sinus thrombosis) and superficial upper extremity VTE; (b) peripherally inserted central catheter (PICC) line-related deep venous thrombosis (DVT) with spontaneous resolution; and (c) renal infarcts, postulated to be secondary to renal arterial thrombosis.

For children with primary SARS-CoV-2 infection and thrombosis (5/385; 1.3%), CHD (40% vs. 2.4%, p-value <.007), use of respiratory support (100% vs. 0%, p-value <.001), and presence of CVC (40% vs. 7%, p-value .04) were more common compared to children without thrombosis (380/385). For children with MIS-C and thrombosis (5/288; 1.7%), obesity (60% vs. 2%, p-value .002), use of respiratory support (40% vs. 1%, p-value .03), and cytokine storm (40% vs. 3%, p-value .012) were more common than in children with MIS-C without thrombosis (283/288) (Table 3).

New hemorrhagic events were reported in 18 children (18/915; 2%): 11 with primary SARS-CoV-2 infection (11/385; 2.8%), six with MIS-C (6/288; 2%), and one with incidental SARS-CoV-2 infection (1/242; 0.4%) (Table 4). All hemorrhagic episodes occurred during the course of hospitalization, with none observed at the time of presentation. Information about previous episodes of hemorrhage was not
| Age (years) | Sex | Lowest platelet count (×10^9/L) | Anatomic site | Severity | Case definition | Underlying comorbidity | Anticoagulation | Management | SARS CoV-2 or MIS-C | Additional history |
|------------|-----|-------------------------------|---------------|----------|----------------|----------------------|----------------|------------|------------------|--------------------|
| 1          | 13  | M                             | Nose          | 4        | Primary SARS-CoV-2 infection | Relapsed ALL, thrombocytopenia fungal infection | Yes (LMWH) | Tranexamic acid, transfusion-packed RBCs, plasma platelets cryoprecipitate | Famipinavir | Patient died |
| 2          | 2.5 | F                             | Nose, abdominal intratumor | 3        | Primary SARS-CoV-2 infection | Neuroblastoma thrombocytopenia CMV infection | No | Surgical intervention, transfusion: packed RBCs, plasma platelets | IVIG, remdesivir |
| 3          | 0.5 | M                             | Lower GI      | 3        | Primary SARS-CoV-2 infection | Bernard Soulier syndrome | No | Transfusion: packed RBCs | |
| 4          | 17  | F                             | Postpartum vaginal | 3        | Primary SARS-CoV-2 | Gestational HTN, asthma | Yes (LMWH) | Transfusion: packed RBCs | |
| 5          | 0.5 | M                             | Lung          | 3        | Primary SARS-CoV-2 infection | Congenital heart disease | No | Transfusion: plasma | IVIG, tocilizumab, interferon |
| 6          | 1   | M                             | Lower GI      | 2        | Primary SARS-CoV-2 infection | None | Yes (LMWH) | None | None |
| 7          | 17  | M                             | Nose, lung    | 2        | Primary SARS-CoV-2 infection | Kidney injury, hepatitis, asthma | Yes (DOAC) | None | Steroids |
| 8          | 17  | F                             | Lung          | 2        | Primary SARS-CoV-2 infection | None | No | None | None |
| 9          | 5   | F                             | Upper GI      | 2        | Primary SARS-CoV-2 infection | Global developmental delay, Mallory Weiss tear | No | None | None |
| 10         | 9   | F                             | Upper GI      | 2        | Primary SARS-CoV-2 infection | Global developmental delay, seizures | No | None | None |
| 11         | 3.5 | M                             | Upper GI      | 2        | Primary SARS-CoV-2 infection | Obesity | No | Pantoprazole |
| 12         | 16  | M                             | CNS           | 4        | MIS-C | ALL, thrombocytopenia systemic infection | No | Transfusion: platelets, packed RBCs | IVIG, prednisone | Past history of DVT |
| 13         | 8   | F                             | Upper GI      | 3        | MIS-C | Systemic infection, cerebral palsy | Yes (aspirin) | Transfusion: frozen plasma | IVIG, anakinra, aspirin |

(Continues)
| Age (years) | Sex | Lowest platelet count (×10⁹/L) | Anatomic site | Severity | Case definition | Underlying comorbidity | Anticoagulation | Hemorrhage | SARS CoV-2 or MIS-C | Additional history |
|-------------|-----|-------------------------------|---------------|----------|----------------|-----------------------|----------------|------------|------------------|------------------|
| 14          | 13  | M                             | Lower GI      | 2        | MIS-C          | None                  | No            | None       | IVIG, steroids interferon |
| 15          | 13  | F                             | Nose          | 1        | MIS-C          | Castleman's disease thrombocytopenia Yes (aspirin) | None         | IVIG, anakinra aspirin | Cytokine storm |
| 16          | 10  | M                             | Upper GI      | 3        | MIS-C          | Obesity systemic infection Yes (DOAC) | Transfusion: packed RBCs | IVIG, steroids | Also had pulmonary micro-emboli |
| 17          | 86  | M                             | Urinary tract | 1        | MIS-C          | Factor V Leiden heterozygous No | None         | IVIG, aspirin | Also had hematuria |
| 18          | 6   | M                             | Upper GI      | 3        | Incidental SARS-CoV-2 ALL thrombocytopenia No | Transfusion: platelets, packed RBCs | Febrile neutropenia |

Note: Lowest platelet count recorded during hospital admission; not correlated with timing of hemorrhage. Age: age in years upon hospital admission; severity: determined based on World Health Organization-modified bleeding scale.

Abbreviations: ALL, acute lymphoblastic leukemia; DVT, deep vein thrombosis; GI, gastrointestinal tract; IVIG, intravenous immune globulin; MIS-C, multisystem inflammatory syndrome in children; PRBCs, packed red blood cells; TXA, tranexamic acid.

*Patients 16 and 17, also mentioned in Table 2, had thrombosis.*
**Table 5** The prevalence of pro-hemorrhagic comorbidities in children hospitalized with SARS-CoV-2 infection or MIS-C

| Children with primary SARS-CoV-2 infection (N = 385) | No hemorrhage (N = 374) | Hemorrhage (N = 11) | p-Value |
|---------------------------------------------------|-------------------------|---------------------|---------|
| Gender                                            | 274 (73%)               | 8 (73%)             |         |
| Systemic infection                                | 226 (60%)               | 3 (27%)             |         |
| Anticoagulation therapy and/or antiplatelet therapy | 157 (42%)               | 8 (73%)             |         |
| ICU admission                                     | 113 (30%)               | 4 (36%)             | .04     |
| Age ≥10 years                                     | 86 (23%)                | 5 (45%)             |         |
| Thrombocytopenia                                  | 33 (8%)                 | 2 (18%)             |         |
| Presence of CVC                                   | 26 (7%)                 | 3 (27%)             | .03     |
| Congenital heart disease                          | 13 (3.4%)               | 1 (9%)              |         |
| Cytokine storm                                    | 5 (1.3%)                | 1 (9%)              |         |
| Kidney disease (acute or chronic)                 | 4 (1%)                  | 1 (9%)              |         |

| Children with MIS-C (N = 288) | No hemorrhage (N = 282) | Hemorrhage (N = 6) | p-Value |
|-------------------------------|-------------------------|-------------------|---------|
| Anticoagulation therapy and/or antiplatelet therapy | 219 (78%)               | 3 (50%)           |         |
| Gender                        | 155 (55%)               | 4 (57%)           |         |
| ICU admission                  | 114 (41%)               | 2 (33%)           |         |
| Age ≥10 years                  | 64 (23%)                | 3 (50%)           |         |
| Systemic infection             | 53 (20%)                | 3 (50%)           |         |
| Presence of CVC                | 15 (5.3%)               | 2 (33%)           |         |
| Cytokine storm                 | 9 (3.2%)                | 2 (33%)           | .001    |
| Thrombocytopenia               | 1 (0.3%)                | 2 (33%)           | .02     |
| Congenital heart disease       | 0                       | 0                 |         |
| Kidney disease (acute or chronic) | 0                     | 0                 |         |

Note: Age ≥10 years: age at the time of admission to hospital. Abbreviations: CVC, central venous catheter; MIS-C, multisystem inflammatory syndrome in children.

recorded. Two (2/6; 34%) patients with hemorrhage and MIS-C developed cytokine storm and two (2/6; 34%) experienced both hemorrhage and thrombosis.

Six patients (6/18; 33%) who experienced hemorrhage had thrombocytopenia, five were receiving anticoagulation or antiplatelet therapy (5/18; 28%), and one (1/15; 5%) was thrombocytopenic and receiving anticoagulation prophylaxis as well.

Fifty percent of the patients (N = 9/18) had severe hemorrhage (WHO grade 3 or higher) and required transfusion of blood products and/or surgical intervention to control the bleeding. Children with severe hemorrhage (WHO grades 3–4) were more likely to have thrombocytopenia (5/6; 83%; p-value .04) versus those with minor hemorrhage (grades 1–2). The proportion of children with severe hemorrhage was similar with (4/7) and without the use of anticoagulation or antiplatelet therapy (4/10). However, as the temporal relationship between use of anticoagulation and hemorrhage occurrence during hospital admission was not available, comparative statistics could not be performed. Seven patients (7/18; 39%) required ICU admission. One patient died due to sepsis and relapse of leukemia.

Comorbid medical conditions that predispose to hemorrhage were compared between children who developed hemorrhage during hospitalization and those without (Table 5). In children with primary SARS-CoV-2 infection and hemorrhage (11/385), a significantly higher proportion had age >10 years at the time of hospitalization (5/11, 50% vs. 86/374, 23%; p-value .04) and a CVC present (26/374, 30% vs. 3/11, 7%; p-value .03). Thrombocytopenia (2/6, 28.5% vs. 1/282, 0.3%; p-value .001) and cytokine storm (2/6, 28.5% vs. 9/282, 3%; p-value .02) were significantly common in children with MIS-C and hemorrhage (6/288) versus MIS-C patients without hemorrhage.

Overall, patients with MIS-C did not have a higher prevalence of hemorrhage (2.1% vs. 2.6%; p-value .8) or thrombosis (1.7% vs. 1.3%; p-value .2) compared to patients with primary SARS-CoV-2 infection. All children with thrombosis had at least one prothrombotic factor in addition to SARS-CoV-2 and hospitalization with seven having
two or more additional factors. Majority of children with hemorrhage (16/18; 89%) also had additional comorbid conditions predisposing to hemorrhage.

The hematologic laboratory parameters (white blood cell count [WBC], hemoglobin, platelet count, INR, PTT, D-dimer, and fibrinogen) were collected but could not be linked by time with thrombosis or hemorrhage (Tables 1 and 2). Median D-dimer levels were noted to be significantly higher in patients with thrombosis; both among the ones with MIS-C and SARS-CoV-2 infection (12.6 vs. 3.1 mg/dl, p-value .01; 11 vs. 1.5 mg/dl, p-value .02).

4 | DISCUSSION

This study describes the clinical spectrum of new bleeding and thrombotic events in a large cohort of hospitalized children with SARS-CoV-2 infection or MIS-C. When compared to hospitalized adults, the rates of thrombosis and hemorrhage in children were markedly lower and were not associated with mortality.8 The majority of children with new of thrombosis and hemorrhage in children were markedly lower and infection or MIS-C. When compared to hospitalized adults, the rates thrombotic events in a large cohort of hospitalized children with SARS-CoV-2 infection provides variable rates of thrombosis. From March 2020 to December 2020, the reported prevalence of thrombotic events in children with primary SARS-CoV-2 infection was 0.8% (N = 8/971), 1.2% (5/398), and 26% (7/27).36–39 Between January 2021 to November 2021, the prevalence was 0.7% (4/537) to 2.1% (9/426).14,40 In children with MIS-C, the reported rate of thrombosis ranged from 4.3% (8/186) to 6.5% (9/138) in larger studies,14,41 with two small studies reporting no thrombotic events in MIS-C patients (N = 6 and N = 30).15,42

The prevalence of thrombosis in children with primary SARS-CoV-2 infection in the current study is in alignment with previous reports. However, the thrombosis rates are markedly lower in MIS-C patients of this cohort compared with previous studies. The specificity of diagnostic criteria used for MIS-C in this study, younger age of admission to hospital (median age 6 vs. 10 years in previous large cohort14), and male predominance are some of the potential reasons for a lower thrombosis prevalence in MIS-C patients.

Hemorrhage occurred in 2% of children, and was graded as severe in half of the cases. The rate of hemorrhage and its severity is in alignment with previously reported adult and pediatric literature on SARS-CoV-2 infection and MIS-C.14 Hemorrhage was most frequently observed in children with underlying pro-hemorrhagic conditions (thrombocytopenia, cytokine storm, and CHD) or with severe disease (older age and CVC presence likely the surrogate markers of disease severity).21,22 Hemorrhage in children with thrombocytopenia had a higher risk of severe hemorrhage; however, hemorrhage prevalence or severity was not altered by administration of anticoagulation agents. As expected, children with thrombocytopenia had a higher risk of severe hemorrhage; however, hemorrhage prevalence or severity was not altered by administration of anticoagulation or antiplatelet agents. Adult COVID-19 inpatients are reported to have a similar rate of hemorrhagic episodes (2.8%), linked with increased mortality at 28 days.45

The relationship between SARS-CoV-2 infection and hemorrhage severity in pediatric inpatients is currently unclear. In those with pre-existing hemorrhagic conditions, SARS-CoV-2 or MIS-C may alter the overall bleeding risk and severity, but additional research is needed to ascertain that effect.

This study is unique as it describes hematologic complications of a large, diverse cohort of pediatric inpatients with SARS-CoV-2 infection. The main limitations include its retrospective design and missing patient data. It was not possible to link the time of the laboratory results with clinical events (hemorrhage/thrombosis). Information on the time of initiation of anticoagulation in relation to the timing of hemorrhage or thrombosis during hospitalization, its dose, and duration were not recorded consistently. Hence, the correlation of hemorrhage with the use of anticoagulation agents could not be analyzed conclusively. Small or subsegmental pulmonary embolic events may have not been diagnosed, as CT angiogram of chest was used in a very small
number of children (63/915; 7%) and hence underreported. Rate of obesity in this cohort may also be underreported, as it was not defined based on BMI. The event rate for hemorrhage and thrombosis was low, which led to inability in performing regression analyses and provided uncertainty in the results of comparative statistics.

In conclusion, the dysregulation of hemostasis in hospitalized children with SARS-CoV-2 and MIS-C is more likely to occur among those with underlying comorbid conditions. The rates of thromboses in children are markedly lower than adults, with no observed correlation to prognosis. Ongoing research is critical to determine appropriate management of coagulopathy and thromboprophylaxis in pediatric patients, especially with the advent of variant strains of SARS-CoV-2 virus.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Sarah Tehseen https://orcid.org/0000-0002-1794-9672
Rolando Ulloa-Gutierrez https://orcid.org/0000-0002-9157-9227
Gabriela Ivankovich-Esco https://orcid.org/0000-0001-9675-3143
Lani Lieberman https://orcid.org/0000-0002-3633-0728

REFERENCES
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497-506.
2. Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. CMAJ. 2020;192(21):E583.
3. Klok FA, Kruijp MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
4. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184-186.
5. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
6. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786-787.
7. Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103-2109.
8. Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-e440.
9. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088-1095.
10. Martins MM, Prata-Barbosa A, da Cunha A. Update on SARS-CoV-2 infection in children. Paediatr Int Child Health. 2021;41(1):56-64.
11. Oualha M, Bendavid M, Berteloot L, et al. Severe and fatal forms of COVID-19 in children. Arch Pediatr. 2020;27(5):235-238.
12. Drouin O, Hepburn CM, Farrar DS, et al. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. CMAJ. 2021;193(8):E1483-E1493.
13. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021;180(3):689-697.
14. Whitworth H, Sartain SE, Kumar R, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021;138(2):190-198.
15. Del Borrello G, Giraudo I, Bondone C, et al. SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost. 2021;19(2):522-530.
16. Freedman S. Multisystem inflammatory syndrome in children and adolescents with COVID-19. World Health Organization; 2020.
17. Fogarty PF, Tarantino MD,Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(1):79-87.
18. Ravelli A, Minoia F, Davi S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Ann Rheum Dis. 2016;75(3):481-489.
19. Mahajerin A, Branchford BR, Amankwah EK, et al. Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models. Haematologica. 2015;100(8):1045-1050.
20. Branchford BR, Mahajerin A, Raffini L, et al. Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(11):2274-2278.
21. Decousus H, Tapson VF, Bergmann J-F, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79.
22. Pant C, Sankararaman S, Deshpande A, et al. Gastrointestinal bleeding in hospitalized children in the United States. Curr Med Res Opin. 2014;30(6):1065-1069.
23. White LJ, Fredericks R, Mannarino CN, et al. Epidemiology of bleeding in critically ill children. J Pediatr. 2017;184:114-119.e6.
24. Vandenbroucke JP, van Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
25. Middeldorp S, Coppen M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.
26. Massalska MA, Gober HJ. How children are protected from COVID-19? A historical, clinical, and pathophysiological approach to address COVID-19 susceptibility. Front Immunol. 2021;12:646894.
27. Dhochak N, Singhal T, Kabra SK, et al. Pathophysiology of COVID-19: why children fare better than adults? Indian J Pediatr. 2020;87(7):537-546.
28. Sentzouris G, Scriven RJ, Lee TK, et al. Pediatric venous thromboembolism in relation to adults. J Vasc Surg. 2012;55(6):1785-1793.
29. Raffini L, Huang Y-S, Witmer C, et al. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
30. Vu LT, Nobuhara KK, Lee H, et al. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg. 2008;43(6):1095-1099.
with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021;143(2):135-144.
32. Haji Esmaeil Memar E, Pourakbari B, Gorgi M, et al. COVID-19 and congenital heart disease: a case series of nine children. World J Pediatr. 2021;17(1):71-78.
33. Faustino EVS. Central venous catheter-associated deep venous thrombosis in critically ill children. Semin Thromb Hemost. 2018;44(1):52-56.
34. Mendoza-Pinto C, Escárcega RO, García-Carrasco M, et al. Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications. J Intern Med. 2020;288(6):737-739.
35. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059-1063.
36. Zaffanello M, Piacentini G, Nosetti L, et al. Thrombotic risk in children with COVID-19 infection: a systematic review of the literature. Thromb Res. 2021;205:92-98.
37. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346.
38. Al-Ghafry M, Aygun B, Appiah-Kubi A, et al. Are children with SARS-CoV-2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients. Pediatr Blood Cancer. 2020;67(12):e28737.
39. Mitchell WB, Davila J, Keenan J, et al. Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy. Pediatr Blood Cancer. 2021;67(12):e28975.
40. Beslow LA, Linds AB, Fox CK, et al. Pediatric ischemic stroke: an infrequent complication of SARS-CoV-2. Ann Neurol. 2021;89(4):657-665.
41. Al-Ghafry M, Vagrecha A, Malik M, et al. Multisystem inflammatory syndrome in children (MIS-C) and the prothrombotic state: coagulation profiles and rotational thromboelastometry in a MIS-C cohort. J Thromb Haemost. 2021;19(7):1764-1770.
42. Ankola AA, Bradford VR, Newburger JW, et al. Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children. Pediatr Blood Cancer. 2021;68(12):e29355.
43. Odegard KC, Zurakowski D, Hornykewycz S, et al. Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg. 2007;83(5):1797-1803.
44. Hanson SJ, Mahajerin A, Petty JK, et al. Risks of venous thrombosis and bleeding in critically ill adolescents after trauma or major surgery. J Pediatr Surg. 2021;56(2):302-308.
45. Al-Samkari H, Gupta S, Leaf RK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med. 2021;174(5):622-632.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Tehseen S, Williams S, Robinson J, et al. Thrombosis and hemorrhage experienced by hospitalized children with SARS-CoV-2 infection or MIS-C: Results of the PICNIC registry. Pediatr Blood Cancer. 2022;69:e29793. https://doi.org/10.1002/pbc.29793